首页> 外文OA文献 >Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972

【2h】

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972

机译：替莫唑胺二线化疗治疗PCV（丙卡巴肼，洛莫司汀和长春新碱）化疗后复发性少突胶质细胞瘤：EORTC脑肿瘤组II期研究26972

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bent M.J. (Martin) van den; Chinot O.; Boogerd W. (Willem); Bravo Marques J.; Taphoorn M.J. (Martin); Kros J.M. (Johan); Rijt C.C.D. (Carin) van der; Vecht C.J.; Beule N. de; Baron B.;
展开▼
作者单位

展开▼
年度 2003
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. [J] . Van Den Bent MJ, Chinot O, Boogerd W, Annals of oncology: official journal of the European Society for Medical Oncology . 2003,第4期

机译：替莫唑胺二线化疗用于PCV（丙卡巴嗪，洛莫司汀和长春新碱）化疗后复发的少突胶质细胞瘤：EORTC脑肿瘤组II期研究26972。
2. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951 [J] . VanDenBentM.J., BrandesA.A., TaphoornM.J.B., Journal of Clinical Oncology . 2013,第3期

机译：新诊断的间变性少突胶质细胞瘤的辅助卡巴嗪，洛莫斯汀和长春新碱化学治疗：EORTC脑肿瘤组研究的长期随访26951
3. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951 [J] . Erdem-EraslanL., GravendeelL.A., DeRooiJ., Journal of Clinical Oncology . 2013,第3期

机译：脑胶质瘤的内在分子亚型可预后，并预测脱羧性少突神经胶质脑肿瘤的辅助卡巴肼，洛莫司汀和长春新碱化疗与其他预后因素的结合获益：EORTC研究报告26951
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine Lomustine and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951 [O] . Lale Erdem-Eraslan, Lonneke A. Gravendeel, Johan de Rooi, -1

机译：脑胶质瘤的内在分子亚型可预后并预测佐普卡巴嗪洛莫斯汀和长春新碱化学疗法与间变性少突神经胶质脑肿瘤的其他预后因素相结合的优势：EORTC研究26951的报告
6. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 [O] . M.J. van den Bent, O. Chinot, W. Boogerd, 2003

机译：二线化疗与替代唑替替替替替替替替替氏术术后PCV（ProCarbazine，Lomustine和Vincristine）化疗：Eortc脑肿瘤组II II研究26972

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972

著录项

引文网络

相似文献

相关主题

期刊订阅